‘We simply cannot sustain’: Idorsia weighs layoffs, deals, pipeline trims to bring cost down

Idor­sia could cut “up to 500 po­si­tions” in R&D and as­so­ci­at­ed sup­port func­tions as the Swiss drug­mak­er finds ways to save cash un­til it can turn things around with its in­som­nia drug, Qu­viviq.

The cost re­duc­tion ini­tia­tive car­ries the am­bi­tious goal of chop­ping cash burn at its Allschwil head­quar­ters by half, start­ing ear­ly next year. To that end, it will re­view the pipeline and prod­uct port­fo­lio to find any projects that can ei­ther be halt­ed or hand­ed off through deals.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN